Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT04124302
Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 72
- Registration Number
- NCT04019821
- Locations
- 🇵🇱
Department of Pediatric Diabetology and Pediatrics, Pediatric Teaching Clinical Hospital, Warsaw, Poland
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 384
- Registration Number
- NCT03359837
- Locations
- 🇨🇳
CHINA, China, China
Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2021-12-06
- Target Recruit Count
- 300
- Registration Number
- NCT03328845
- Locations
- 🇪🇸
Regional University Hospital of Málaga, Málaga, Spain
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Kinderkrankenhaus auf der Bult
- Target Recruit Count
- 14
- Registration Number
- NCT02914886
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT02910518
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT02685449
- Locations
- 🇵🇱
Medical University, Warsaw, Poland
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- HealthPartners Institute
- Target Recruit Count
- 49
- Registration Number
- NCT02503501
- Locations
- 🇺🇸
HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States
🇺🇸HealthPartners Riverside, Minneapolis, Minnesota, United States
Investigation of the Safety of Intranasal Glulisine in Down Syndrome
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- HealthPartners Institute
- Target Recruit Count
- 12
- Registration Number
- NCT02432716
- Locations
- 🇺🇸
HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States
Normal Versus Dual Wave Insulin Bolus for High-protein Food
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT02276859
- Locations
- 🇵🇱
Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.